Skip to main content
. Author manuscript; available in PMC: 2009 Apr 8.
Published in final edited form as: Arch Gen Psychiatry. 2008 Feb;65(2):135–144. doi: 10.1001/archpsyc.65.2.135

Table 1.

Demographics of White Participants Who Provided Genetic Samples by Treatment Conditiona

Medical Management (No CBI)
CBI + Medical Management
Total Sample
Placebo
Naltrexone
Hydrochloride
Placebo
Naltrexone
Hydrochloride

Characteristic
Asn40
(n=469)
Asp40
(n=135)
Asn40
(n=126)
Asp40
(n=35)
Asn40
(n=115)
Asp40
(n=31)
Asn40
(n=109)
Asp40
(n=33)
Asn40
(n=119)
Asp40
(n=36)
Demographics
  Age, y, mean (SD) 45.6 (10.49) 44.8 (10.51) 45.2 (10.09) 46.1 (12.08) 45.7 (11.17) 42.5 (10.01) 45.8 (10.05) 45.6 (9.53) 45.7 (10.73) 44.8 (10.28)
  Sex, No. (%) M 332 (70.8)  91 (67.4)  91 (72.2)  23 (65.7)  77 (67.0)  21 (67.7)  81 (74.3)  24 (72.7)  83 (69.7)  23 (63.9) 
  Married, No. (%) 214 (45.6)  52 (38.5)  50 (39.7)  10 (28.6)  51 (44.3)  11 (35.5)  61 (56.0)  15 (45.5)  52 (43.7)  16 (44.4) 
  Employed, No. (%) 344 (73.3)  110 (81.5)  91 (72.2)  31 (88.6)  88 (76.5)  20 (64.5)  82 (75.2)  26 (78.8)  83 (69.7)  33 (91.7) 
  Education≤high school, No. (%) 124 (26.4)  35 (25.9)  36 (28.6)  11 (31.4)  30 (26.1)  8 (25.8)  25 (22.9)  11 (33.3)  33 (27.7)  5 (13.9) 
  Current smoker, No. (%) 206 (43.9)  58 (43.0)  51 (40.5)  13 (37.1)  54 (47.0)  13 (41.9)  39 (35.8)  16 (48.5)  62 (52.1)  16 (44.4) 
Alcohol use severity indicators, mean (SD)
   % of days abstinentb 23.9 (24.58) 21.9 (23.91) 24.5 (25.37) 19.9 (23.99) 23.9 (24.38) 26.9 (27.73) 19.8 (22.44) 21.6 (23.38) 27.1 (25.55) 19.6 (20.99)
   Drinks per drinking dayb 12.6 (7.54)  11.8 (7.14)  12.4 (6.69)  12.3 (8.37)  12.6 (8.37)  13.4 (9.14)  12.4 (7.36)  11.5 (5.19)  12.8 (7.81)  10.2 (5.10) 
   Overall drinks per dayb 9.3 (6.18)  9.2 (6.78)  9.2 (6.17)  9.5 (7.38)  9.2 (6.14)  10.5 (9.48)  9.7 (5.97)  8.6 (4.15)  9.0 (6.47)  8.3 (5.27) 
   Heavy drinking daysb 20.0 (8.36)  20.6 (8.10)  20.1 (8.40)  20.4 (7.98)  19.9 (8.49)  19.8 (9.10)  21.1 (7.89)  21.2 (7.90)  19.1 (8.58)  20.9 (7.79) 
   DSM-IV symptoms 5.5 (1.26)  5.5 (1.23)  5.6 (1.29)  5.4 (1.14)  5.5 (1.27)  5.6 (1.36)  5.6 (1.21)  5.6 (1.19)  5.5 (1.27)  5.3 (1.26) 
   Alcohol dependence scorec 16.6 (7.26)  16.9 (7.93)  17.2 (7.30)  16.6 (7.45)  16.2 (7.43)  18.1 (10.36)  16.5 (6.99)  17.7 (7.18)  16.6 (7.36)  15.3 (6.58) 
   OCDS score 26.0 (7.11)  26.5 (7.24)  26.7 (7.50)  24.6 (6.53)  25.2 (7.33)  25.8 (7.91)  26.8 (5.96)  28.2 (7.95)  25.4 (7.37)  27.2 (6.38) 
   Drinking consequences scored 47.8 (19.91) 46.5 (20.52) 49.6 (20.06) 46.8 (21.31) 46.2 (20.05) 45.2 (21.52) 48.1 (19.78) 47.0 (20.61) 47.2 (19.81) 47.1 (19.58)
   GGT, IU/L, 68.8 (112.4) 61.8 (82.49) 81.0 (168.7) 59.3 (63.46) 62.4 (74.90) 63.3 (80.15) 60.3 (53.88) 64.6 (99.93) 69.7 (107.4) 60.5 (86.51)
   % CDT 3.5 (2.06)  3.2 (1.84)  3.7 (2.55)  3.3 (2.27)  3.3 (1.84)  3.1 (1.59)  3.5 (1.95)  3.5 (2.12)  3.5 (1.77)  2.9 (1.14) 
   No. (%)
    GGT>63 IU/L 137 (29.2)  33 (24.4)  36 (28.6)  9 (25.7)  32 (27.8)  8 (25.8)  34 (31.2)  10 (30.3)  35 (29.4)  6 (16.7) 
    CDT>2.5% 227 (48.4)  58 (43.0)  63 (50.0)  16 (45.7)  50 (43.5)  12 (38.7)  57 (52.3)  17 (51.5)  57 (47.9)  13 (36.1) 

Abbreviations: CBI, combined behavioral intervention; CDT, carbohydrate-deficient transferrin; GGT, γ-glutamyltransferase; OCDS, obsessive compulsive drinking scale.

SI conversion factor: To convert GGT to microkatals per liter, multiply by 0.01667.

a

Differences across treatment and genotypes were not significant. For the total sample and within each treatment combination, Asn40 (Asn40/Asn40 homozygote) individuals were compared with Asp40 carriers (Asn40Asp or Asp40Asp). For those receiving CBI plus medical management and naltrexone, “employed” had P=.004. All other P values were greater than .05.

b

In the 30 days before randomization.

c

Assessed using the Alcohol Dependence Scale.57

d

Assessed using the Drinker Inventory of Consequences scale.58